Form 4: Syndax Pharmaceuticals Director Aleksandra Rizo Acquires 35,000 Stock Options
SEC Form 4 Filing
Director Aleksandra Rizo acquired 35,000 stock options in Syndax Pharmaceuticals on May 15, 2024.
Summary
- On May 15, 2024, Aleksandra Rizo, a director of Syndax Pharmaceuticals Inc., acquired 35,000 stock options.
- The exercise price of these options is $21.94.
- The options vest monthly over a three-year period, with the expiration date set for May 15, 2034.
- Following the transaction, Rizo directly owns 35,000 derivative securities.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a routine disclosure of stock option acquisition. The director's acquisition could be seen as a positive signal, but it's not definitive.
Positives
- The acquisition of stock options by a director may signal confidence in the company's future performance.
Industry Context
This is a standard SEC Form 4 filing, which is common for corporate insiders reporting transactions in their company's securities. It provides transparency into the trading activities of individuals with access to non-public information.
Stakeholder Impact
- The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/15/2024 | Date of transaction: Aleksandra Rizo acquired 35,000 stock options. |
| 05/15/2034 | Expiration date of the stock options. |
| 05/16/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.